AIV007

DRUG3 trials

Sponsors

AiViva BioPharma, Inc.

Conditions

Diabetic Macular EdemaMacular EdemaNeovascular (Wet) Age-Related Macular DegenerationNeovascular Age-related Macular Degeneration

Phase 1

Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration

CompletedNCT04422899

AiViva BioPharma, Inc.Neovascular Age-related Macular Degeneration

Start: 2020-08-28End: 2022-02-28Updated: 2024-12-27

Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)

Active, not recruitingNCT05698329

AiViva BioPharma, Inc.Diabetic Macular Edema, Macular Edema, Neovascular Age-related Macular Degeneration

Start: 2023-03-02End: 2025-04-01Updated: 2025-03-06

Phase 2

Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration

Not yet recruitingNCT07557121

AiViva BioPharma, Inc.Neovascular (Wet) Age-Related Macular Degeneration

Start: 2026-07-01End: 2027-08-23Target: 35Updated: 2026-04-29